Topilutamide
Topilutamide (INN) = fluridil: a topical nonsteroidal androgen-receptor antagonist marketed as Eucapil (Czech Republic / EU) as a cosmetic/OTC for androgenetic alopecia. It acts locally (it is rapidly inactivated), but the clinical evidence is limited (one small study).
WHAT IS TOPILUTAMIDE?
Detailed overview
Topilutamide (the international nonproprietary name; better known as fluridil) is a topical, nonsteroidal androgen-receptor antagonist that Sovak and colleagues "rationally designed" for hair loss: the molecule acts on the scalp, but once absorbed it rapidly hydrolyzes to inactive metabolites, so in principle it has no systemic antiandrogen effect. Under the brand name Eucapil it is marketed in the Czech Republic and a few EU markets as a cosmetic/OTC for androgenetic alopecia, so unlike clascoterone/pyrilutamide/RU58841 this is actually an AVAILABLE product. The clinical evidence, however, is LIMITED: the main published data come from a small, vehicle-controlled early clinical study (Sovak, PMID 12174057), which described good tolerability, an absence of systemic antiandrogen effect and favorable signs in hair outcomes. There is no large confirmatory phase 3 trial, so the evidence is weaker than that for minoxidil/finasteride.
Other name / brand
Fluridil · Eucapil (Czech Republic/EU)
Status
Marketed cosmetic/OTC (EU); not an FDA-approved drug
Mechanism of action
Topical androgen-receptor antagonist (rapid inactivation → local action)
Evidence
Limited: one small vehicle-controlled study (Sovak 2002)
Dosing
Eucapil: typically once daily on the scalp (per the product instructions)
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 3
- Local scalp reactions: mild redness, itching or dryness at the application site; in the (small) clinical study tolerability was good, with no systemic antiandrogen symptoms.
- Limited evidence: efficacy and long-term safety rest on small, early clinical data and cosmetic-marketing experience; there is no large confirmatory phase 3 trial.
- Designed for local action: the molecule deliberately hydrolyzes quickly to inactive metabolites, so systemic antiandrogen effect is minimal – but the full human safety picture rests on a small sample.
Contraindications · 3
- Known hypersensitivity to topilutamide (fluridil) or the vehicle.
- Broken, inflamed or infected scalp: withhold until it heals.
- Pregnancy and breastfeeding: although systemic exposure is minimal by design, avoid or discuss with a physician due to limited data.
Related Hair & Skin
Same therapeutic category
Studies
Related research and clinical findings
Telegram
Have a question about Topilutamide?
Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.